Novavax Begins Phase 3 Trial of COVID-19 Vaccine Candidate in United Kingdom

Reuters  |

Image source: Novavax

(Reuters) - Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in the United Kingdom in partnership with the government’s Vaccines Taskforce, sending the company’s shares up 6% after the bell.

The study is expected to enroll up to 10,000 participants aged between 18 and 84 years and comes after the vaccine candidate produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial.

Data from the trial - likely over the next four to six weeks - will support regulatory submissions for license in the UK, EU and other countries.

The company has previously said it expects to file for U.S. approval of the vaccine in December.

Novavax is among global drugmakers racing to develop a vaccine for COVID-19, for which there are no current treatments or vaccines approved.

The trial will enroll at least 25% of participants over the age of 65 and prioritize groups most affected by the COVID-19, the company said.

Novavax said it could produce up to 2 billion annualized doses, once all capacity is brought online by mid-2021.

Reuters reported on Wednesday that the EU was close to concluding preliminary talks with the company for its potential COVID-19 shot.

Meanwhile, Britain recorded its highest number of daily cases of COVID-19 on Thursday at 6,634, reflecting a second wave of infections sweeping through the country but also a much higher level of testing than during the first wave.

Reporting by Trisha Roy in Bengaluru; Editing by Aditya Soni and Sriraj Kalluvila.


Source: Reuters

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

Trending Articles

Bond Yields Have Risen Well Above Stock Dividend Yields. Are They a Buy?
We're at the Tail End of a Classic Video Game Stock Bust
Is Gold Really the Right Place for Your Money?
How Companies Can Succeed in AI Winter: Jeff Kagan
Utility Investing Is a Steady, Buy-and-Hold Play. Just Not in This Market
Why Nuclear Energy Is Now Part of The Road to Renewables
Our Inflation Nightmare Will Flatline in Six Months
California Wants 100% Electric Vehicles By 2035. Will Its Energy Grid Be Ready?

Market Movers

Sponsored Financial Content